A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB023 (Anti-TWEAK) Administered to Subjects With Rheumatoid Arthritis.
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007173/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Phase I study designed to determine the safety and tolerability of a single dose of BIIB023
administered intravenously versus placebo to subjects with RA.
提供机构：
Vivli
创建时间：
2021-06-10
